Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
Yuki Tahata, Ryotaro Sakamori, Ayako Urabe, Naoki Morishita, Ryoko Yamada, Takayuki Yakushijin, Naoki Hiramatsu, Yoshinori Doi, Akira Kaneko, Hideki Hagiwara, Yukinori Yamada, Taizo Hijioka, Masami Inada, Shinji Tamura, Yasuharu Imai, Kunimaro Furuta, Takahiro Kodama, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara – 6 August 2018 – Combination treatment of ledipasvir and sofosbuvir (LDV/SOF) is first‐line treatment for patients with chronic hepatitis C genotype 1 in the United States, Europe, and Japan.